Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive biobank launches to unlock myeloma mysteries

NCT ID NCT06237803

Knowledge-focused Sponsor: European Myeloma Network B.V. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study collects and stores blood and tissue samples from 6,000 people with multiple myeloma and related conditions like smoldering myeloma and MGUS. The goal is to create a shared resource for researchers worldwide to study these diseases and improve patient care. Participants provide samples and basic health information, but no experimental treatments are given.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this biobank could provide a valuable resource for future research into better treatments and understanding of myeloma and related diseases.
What could go wrong
This is an observational study, not a treatment trial. It does not test any new therapy, so there is no direct benefit to participants. The samples are for future research, which may or may not lead to medical advances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 6,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Dec 2037

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients in hospitals in countries that participate in European Myeloma Network (EMN) trials; these patients may be included in upfront trials or in maintenance or relapse trials later during their disease.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects with MGUS, smouldering Multiple Myeloma (SMM) , MM (Multiple Myeloma) (+/- EMD), plasma cell leukemia (PCL) (+/- EMD) * Subjects are ≥ 18 years old. * Subjects have provided written informed consent in accordance with federal, local, and institutional guidelines prior to initiation of any project-specific activities or procedures. 1. Subjects do not have kind of condition that, in the opinion of the Investigators, may compromise the ability of the subjects to give written informed consent and 2. subjects are, in the investigator's opinion, willing and able to comply with the protocol requirements. Exclusion Criteria: * Previous treatment with anti-myeloma therapy (excluding one course of therapy in patients in which urgent therapy is deemed necessary according to physician's discretion, e.g. myeloma-related complications resistant to supportive care). * Subjects have had prior unforeseen (serious) adverse reactions to blood donation including, but not limited to fainting, angina, severe bruising, allergic reactions, or any other adverse events. * Any psychological, familial, sociological and geographical condition potentially hampering compliance with the protocol and follow-up schedule.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Extramedullary myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

extramedullary plasmacytoma monoclonal gammopathy of uncertain significance plasma cell leukemia plasma cell myeloma Smoldering Multiple Myeloma smoldering plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Extramedullary myeloma MGUS Multiple myeloma Plasma cell leukemia Smoldering multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    41 sites in 10 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.O. 'Cardinale G.Panico'

    RECRUITING

    Lecce, Italy

  • A.O. 'SS. Antonio e Biagio'

    RECRUITING

    Alessandria, Italy

  • A.O. S. Maria

    RECRUITING

    Terni, Italy

  • A.O. San Camillo-Forlanini

    RECRUITING

    Roma, Italy

  • A.O. di Rilievo Nazionale A. Cardarelli

    RECRUITING

    Naples, Italy

  • A.O.Spedali Civili di Brescia

    RECRUITING

    Brescia, Italy

  • A.O.U. Careggi

    RECRUITING

    Florence, Italy

  • A.O.U. Città della Salute e della Scienza di Torino - PO Molinette

    RECRUITING

    Torino, Italy

  • A.O.U. Maggiore della Carità

    RECRUITING

    Novara, Italy

  • A.O.U. Policlinico S. Martino - Clinica Ematologica

    RECRUITING

    Genova, Italy

  • A.O.U. Policlinico S. Martino - Ematologia

    RECRUITING

    Genova, Italy

  • A.S.U.R. Regione Marche

    RECRUITING

    Civitanova Marche, Italy

  • AOU Ospedali Riuniti di Ancona

    RECRUITING

    Ancona, Italy

  • Alfred Hospital

    RECRUITING

    Melbourne, Australia

  • Azienda Ospedaliera Universitaria di Udine

    RECRUITING

    Udine, Italy

  • Bari-A.O.U. Consorziale Policlinico - Medicina Interna

    RECRUITING

    Bari, Italy

  • Beaumont Hospital, Dublin, Hematology Department

    RECRUITING

    Galway, Ireland

  • CHUC

    RECRUITING

    Coimbra, Portugal

  • CHUV

    RECRUITING

    Lausanne, Switzerland

  • Chsj - Hosp. Sao Joao

    RECRUITING

    Porto, Portugal

  • Clinic of Hematology, University Clinical Center of Serbia

    RECRUITING

    Belgrade, Serbia

  • Department of Haematology UZ Leuven Gasthuisberg

    RECRUITING

    Leuven, Belgium

  • Fakultní nemocnice

    RECRUITING

    Olomouc, Czechia

  • Fakutni nemocnice Ostrava

    RECRUITING

    Ostrava, Czechia

  • Fundação Champalimaud

    RECRUITING

    Lisbon, Portugal

  • HOCH Health Ostschweiz Kantonsspital St.Gallen

    RECRUITING

    Sankt Gallen, Switzerland

  • I.R.C.C.S. Ospedale Casa Sollievo della Sofferenza

    RECRUITING

    San Giovanni Rotondo, Italy

  • IPOP Porto

    RECRUITING

    Porto, Portugal

  • KUK Linz

    RECRUITING

    Linz, Austria

  • Medical University Vienna

    RECRUITING

    Vienna, Austria

  • Nemocnice Havířov

    RECRUITING

    Havířov, Czechia

  • Nemocnice Nový Jičín

    RECRUITING

    Nový Jičín, Czechia

  • Nemocnice Pelhrimov

    RECRUITING

    Pelhřimov, Czechia

  • Ospedale S. Eugenio

    RECRUITING

    Roma, Italy

  • Policlinico S Orsola Malpighi

    RECRUITING

    Bologna, Italy

  • Policlinico S. Matteo Fondazione IRCCS - Pavia

    RECRUITING

    Pavia, Italy

  • Regional General Hospital Alexandra Dept of Clinical Therapeutics

    RECRUITING

    Athens, Greece

  • Slezská nemocnice

    RECRUITING

    Opava, Czechia

  • Theagenion Cancer Hospital

    RECRUITING

    Thessaloniki, Greece

  • ULSS8 Berica Ospedale S.Bortolo

    RECRUITING

    Vicenza, Italy

  • Všeobecná Fakultní nemocnice v Praz

    RECRUITING

    Prague, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.